BioSpace News Archive

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 (upamostat)[1] in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. (60/61 patients) as well as South Africa.

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, will participate in the Barclays Global Healthcare Conference 2022 being held on Tuesday, March 15, 2022.

Vaxess Technologies, Inc., an innovative life sciences company developing a pipeline of shelf-stable and simple-to-apply vaccines on the MIMIX patch platform announced occupancy of a second new facility and significant additions to the leadership team.

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the U.S. Food and Drug Administration (FDA) granted the company Breakthrough Device designation for its SOBA-AD diagnostic in development for Alzheimer’s disease (AD).

NEOGEN Corporation announced that it has added a ready-to-use formulation of their Synergize® disinfectant to their biosecurity portfolio.

Pacific GeneTech announces the appointment of Dr. Edward Fryar, Jr. to PGT’s Board of Directors. “We are very honored to have Dr. Fryar join our board. Ed brings to PGT decades of successful management, entrepreneurship and expertise in the poultry industry and his many years of academic research for the agriculture industry.

Tarsier Pharma has expanded its Scientific Advisory Board (SAB).

Deepcell announced two new appointments of former Illumina and Pacific Biosciences life science industry veterans to drive the expansion of Deepcell’s customer support capabilities, partnership ecosystem and corporate development.

Merck, known as MSD outside the United States and Canada, announced that Dr. Julie L. Gerberding, chief patient officer and executive vice president, population health and sustainability, will be retiring from Merck in May 2022.

Dragonfly Therapeutics, Inc. (“Dragonfly”) today announced the achievement of a Phase 1 clinical development milestone for the DF6002/BMS-9896415 IL-12 program.